Market closed

Outlook Therapeutics/$OTLK

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Outlook Therapeutics

Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications.

Ticker

$OTLK
Trading on

Industry

Biotechnology

Employees

24

OTLK Metrics

BasicAdvanced
$33M
Market cap
-
P/E ratio
-$5.93
EPS
0.72
Beta
-
Dividend rate
$33M
0.72
$12.85
$0.87
3.2M
1.072
0.753
-0.311
-39.109
-28.04%
-83.69%
210.93%
-0.39
-0.39
-0.342
17.98%
-5.69%

What the Analysts think about OTLK

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Outlook Therapeutics stock.

OTLK Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

OTLK Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $OTLK

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Outlook Therapeutics stock?

Outlook Therapeutics (OTLK) has a market cap of $33M as of December 21, 2024.

What is the P/E ratio for Outlook Therapeutics stock?

The price to earnings (P/E) ratio for Outlook Therapeutics (OTLK) stock is 0 as of December 21, 2024.

Does Outlook Therapeutics stock pay dividends?

No, Outlook Therapeutics (OTLK) stock does not pay dividends to its shareholders as of December 21, 2024.

When is the next Outlook Therapeutics dividend payment date?

Outlook Therapeutics (OTLK) stock does not pay dividends to its shareholders.

What is the beta indicator for Outlook Therapeutics?

Outlook Therapeutics (OTLK) has a beta rating of 0.72. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.